Medtronic Cardiac Rhythm and Heart Failure
Quick facts
Phase 3 pipeline
- Flecainide or Sotalol or Propafenone · Cardiovascular
These antiarrhythmic drugs suppress abnormal heart rhythms by blocking sodium and/or potassium channels in cardiac tissue, slowing electrical conduction and prolonging the refractory period.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Medtronic Cardiac Rhythm and Heart Failure portfolio CI brief
- Medtronic Cardiac Rhythm and Heart Failure pipeline updates RSS
Frequently asked questions about Medtronic Cardiac Rhythm and Heart Failure
What is Medtronic Cardiac Rhythm and Heart Failure's pipeline?
Medtronic Cardiac Rhythm and Heart Failure has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Flecainide or Sotalol or Propafenone.
Related
- Sector hub: All tracked pharma companies